{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:05:47Z","timestamp":1790179547364,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iLIVER"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.iliver.2026.100253","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:40:15Z","timestamp":1783784415000},"page":"100253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress on hepatitis B surface antigen decline and clearance"],"prefix":"10.1016","volume":"5","author":[{"given":"Yi-Fan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Qi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-462X","authenticated-orcid":false,"given":"Dong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.iliver.2026.100253_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/apt.16172","article-title":"Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss","volume":"53","author":"Brakenhoff","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.iliver.2026.100253_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163175","article-title":"Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA","volume":"132","author":"Ghany","year":"2022","journal-title":"J Clin Investig"},{"issue":"18","key":"10.1016\/j.iliver.2026.100253_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment","volume":"132","author":"Grudda","year":"2022","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.iliver.2026.100253_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/gutjnl-2023-330644","article-title":"Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B","volume":"73","author":"Testoni","year":"2024","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.iliver.2026.100253_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.iliver.2026.100253_bib6","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2017-313811","article-title":"Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers","volume":"67","author":"Pfefferkorn","year":"2018","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.iliver.2026.100253_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41421-025-00803-2","article-title":"Structural polymorphism of the antigenic loop in HBV surface antigen dictates binding of diverse neutralizing antibodies","volume":"11","author":"He","year":"2025","journal-title":"Cell Discov"},{"issue":"17","key":"10.1016\/j.iliver.2026.100253_bib8","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/cncr.34815","article-title":"Increased plasma levels of monocyte chemoattractant protein-1 in patients with hepatitis B virus pre-S2 gene deletion mutation predict a higher risk of hepatocellular carcinoma recurrence after curative surgical resection","volume":"129","author":"Jeng","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.iliver.2026.100253_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.618196","article-title":"Hepatitis B surface antigen suppresses the activation of nuclear factor kappa B pathway via interaction with the TAK1-TAB2 complex","volume":"12","author":"Deng","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.iliver.2026.100253_bib10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/microorganisms9040752","article-title":"An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression","volume":"9","author":"Brancaccio","year":"2021","journal-title":"Microorganisms"},{"issue":"3","key":"10.1016\/j.iliver.2026.100253_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ueg2.12376","article-title":"Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center","volume":"11","author":"Jachs","year":"2023","journal-title":"United Eur Gastroenterol J"},{"issue":"6","key":"10.1016\/j.iliver.2026.100253_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","article-title":"Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2020","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.iliver.2026.100253_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/sjg.SJG_541_16","article-title":"HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: a randomized controlled study","volume":"23","author":"Al Ashgar","year":"2017","journal-title":"Saudi J Gastroenterol"},{"issue":"6","key":"10.1016\/j.iliver.2026.100253_bib14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.iliver.2026.100253_bib15","series-title":"Gut","article-title":"HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)","author":"Dongelmans","year":"2025"},{"issue":"6","key":"10.1016\/j.iliver.2026.100253_bib16","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1097\/HEP.0000000000000658","article-title":"Rate and durability of the clearance of HBsAg in Alaska Native persons with long-term HBV infection: 1982-2019","volume":"79","author":"Bruden","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.iliver.2026.100253_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/hep.32231","article-title":"Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort","volume":"75","author":"Terrault","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.iliver.2026.100253_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12250-020-00290-7","article-title":"Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferon\u03b1-2a","volume":"36","author":"Li","year":"2021","journal-title":"Virol Sin"},{"issue":"1","key":"10.1016\/j.iliver.2026.100253_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/apt.70652","article-title":"HBsAgQuantification-based models for predicting hepatocellular carcinoma risk in nucleos(t)ide analogs-experienced patients with chronic hepatitis B: TheHBsAg-HCCScore","volume":"64","author":"Guo","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.iliver.2026.100253_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000915","article-title":"Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification","volume":"10","author":"Tseng","year":"2026","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.iliver.2026.100253_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s42506-023-00138-4","article-title":"Prevalence of occult hepatitis B virus infection in Egypt: a systematic review with meta-analysis","volume":"98","author":"Azzam","year":"2023","journal-title":"J Egypt Publ Health Assoc"},{"issue":"7","key":"10.1016\/j.iliver.2026.100253_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1111\/jgh.16973","article-title":"Risk of hepatocellular carcinoma decreases after antiviral therapy-induced HBsAg seroclearance","volume":"40","author":"Lee","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.iliver.2026.100253_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20850","article-title":"Survival analysis and development of a prognostic nomogram for patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.iliver.2026.100253_bib24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.62347\/KSLN5850","article-title":"Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection","volume":"15","author":"Ko","year":"2025","journal-title":"Am J Cancer Res"},{"issue":"4","key":"10.1016\/j.iliver.2026.100253_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/hepr.13602","article-title":"Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance","volume":"51","author":"Suzuki","year":"2021","journal-title":"Hepatol Res"},{"issue":"6","key":"10.1016\/j.iliver.2026.100253_bib26","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.iliver.2026.100253_bib27","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/cid\/ciac387","article-title":"Enhanced liver fibrosis score stratifies hepatocellular carcinoma risk in patients with hepatitis B surface antigen seroclearance","volume":"75","author":"Mak","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.iliver.2026.100253_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s10020-025-01194-6","article-title":"New insights into biomarkers and risk stratification to predict hepatocellular cancer","volume":"31","author":"Li","year":"2025","journal-title":"Mol Med"},{"issue":"1","key":"10.1016\/j.iliver.2026.100253_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12072-013-9495-3","article-title":"Loss of HBsAg and antiviral treatment: from basics to clinical significance","volume":"8","author":"Yu","year":"2014","journal-title":"Hepatol Int"},{"key":"10.1016\/j.iliver.2026.100253_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1206720","article-title":"Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity","volume":"13","author":"Zheng","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.iliver.2026.100253_bib31","doi-asserted-by":"crossref","first-page":"10411","DOI":"10.2147\/DDDT.S564254","article-title":"Pegylated interferon-\u03b1-induced functional cure for special populations with chronic hepatitis B virus infection: current trends, challenges and prospection","volume":"19","author":"Zhang","year":"2025","journal-title":"Drug Des Dev Ther"},{"issue":"11","key":"10.1016\/j.iliver.2026.100253_bib32","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.3390\/microorganisms11112731","article-title":"The connection between miR-122 and lymphocytes in patients receiving treatment for chronic hepatitis B virus infection","volume":"11","author":"Manea","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.iliver.2026.100253_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106321","article-title":"Update on combination therapies against HBV in clinical investigations","volume":"245","author":"Mak","year":"2026","journal-title":"Antivir Res"},{"key":"10.1016\/j.iliver.2026.100253_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148111","article-title":"Immune checkpoints on T and NK cells in the context of HBV infection: landscape, pathophysiology and therapeutic exploitation","volume":"14","author":"Dumolard","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.iliver.2026.100253_bib35","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3389\/fimmu.2019.02308","article-title":"Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response","volume":"10","author":"Ma","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.iliver.2026.100253_bib36","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2025.12.006","article-title":"Individualising endpoints in chronic HBV treatment: hbsag loss and beyond","volume":"84","author":"Sonneveld","year":"2026","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2026.100253_bib37","article-title":"Humoral immunity in hepatitis B virus infection: rehabilitating the B in HBV","volume":"4","author":"Vanwolleghem","year":"2022","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.iliver.2026.100253_bib38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2024.06.033","article-title":"Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B","volume":"81","author":"Zhang","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.iliver.2026.100253_bib39","article-title":"Abnormally primed CD8 T cells: the Achilles' heel of CHB","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.iliver.2026.100253_bib40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-025-10823-5","article-title":"Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2025","journal-title":"Hepatol Int"},{"issue":"6176","key":"10.1016\/j.iliver.2026.100253_bib41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.iliver.2026.100253_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virs.2023.12.005","article-title":"Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics","volume":"39","author":"Hu","year":"2024","journal-title":"Virol Sin"},{"issue":"2","key":"10.1016\/j.iliver.2026.100253_bib43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Investig"},{"issue":"61","key":"10.1016\/j.iliver.2026.100253_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi7083","article-title":"Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy","volume":"6","author":"Siwicki","year":"2021","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100253_bib45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.iliver.2026.100253_bib46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.20892\/j.issn.2095-3941.2021.0454","article-title":"Research progress in hepatitis B virus covalently closed circular DNA","volume":"19","author":"Zhang","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.iliver.2026.100253_bib47","article-title":"ASPP2 coordinates ERS-mediated autophagy and apoptosis through mTORC1 pathway in hepatocyte injury induced by TNF-\u03b1","volume":"13","author":"Yao","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.iliver.2026.100253_bib48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40139-015-0093-z","article-title":"TNF\u03b1 in liver fibrosis","volume":"3","author":"Yang","year":"2015","journal-title":"Curr Pathobiol Rep"},{"issue":"7","key":"10.1016\/j.iliver.2026.100253_bib49","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2020-0032","article-title":"IL-27 regulation of innate immunity and control of microbial growth","volume":"6","author":"Povroznik","year":"2020","journal-title":"Future Sci OA"},{"key":"10.1016\/j.iliver.2026.100253_bib50","article-title":"IL-21-deficient T follicular helper cells support B cell responses through IL-27 in patients with chronic hepatitis B","volume":"11","author":"Khanam","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100253_bib51","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/s41598-021-86836-5","article-title":"Bayesian analysis of cytokines and chemokine identifies immune pathways of HBsAg loss during chronic hepatitis B treatment","volume":"11","author":"Narayanan","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.iliver.2026.100253_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000098","article-title":"Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN","volume":"7","author":"Islam","year":"2023","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.iliver.2026.100253_bib53","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.virs.2023.10.007","article-title":"Recent advances in understanding T cell activation and exhaustion during HBV infection","volume":"38","author":"Wang","year":"2023","journal-title":"Virol Sin"},{"issue":"10","key":"10.1016\/j.iliver.2026.100253_bib54","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1136\/gutjnl-2024-332182","article-title":"High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy","volume":"73","author":"Fan","year":"2024","journal-title":"Gut"}],"container-title":["iLIVER"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277294782600037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277294782600037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:41:42Z","timestamp":1790178102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277294782600037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S277294782600037X"],"URL":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100253","relation":{},"ISSN":["2772-9478"],"issn-type":[{"value":"2772-9478","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress on hepatitis B surface antigen decline and clearance","name":"articletitle","label":"Article Title"},{"value":"iLIVER","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100253"}}